Three directors with senior profiles also come to support the key drug development team.
Nantes, France – December 20, 2021, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO), and the appointment of senior directors who reinforce the OSE Immunotherapeutics Development Team.
Laurence de Schoulepnikoff is a seasoned executive who benefits from more than 25 years of experience and a broad expertise in business development and transactions within the pharmaceutical industry, in particular in the negotiation of license contracts and in disposals. / acquisitions. Before joining OSE, Laurence was at AMAL Therapeutics, a Swiss biotechnology company specializing in therapeutic cancer vaccines (acquired by Boehringer Ingelheim in 2019) where she spent 3 years as Chief Operating Officer and Chief Business Officer